里昂发表研究报告指,和黄医药(00013.HK) 2025年业绩好坏参半,其中受商业不利因素影响,其中销售额低于预期,惟净利润高于预期。该行指,2026年肿瘤业务指引暗示著商业复苏即将到来,而新的ATTC产品线将成为未来几年业绩增长的关键驱动力。该行指,将集团今年和明年销售额预测分别调整为降21%和降16%,各年净利润预测则调整为降50%及降27%,其目标价由31.4元下调至30.4元,维持评级为...
Source Link里昂发表研究报告指,和黄医药(00013.HK) 2025年业绩好坏参半,其中受商业不利因素影响,其中销售额低于预期,惟净利润高于预期。该行指,2026年肿瘤业务指引暗示著商业复苏即将到来,而新的ATTC产品线将成为未来几年业绩增长的关键驱动力。该行指,将集团今年和明年销售额预测分别调整为降21%和降16%,各年净利润预测则调整为降50%及降27%,其目标价由31.4元下调至30.4元,维持评级为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.